Ashwin V. Kammula

The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity

Christina K. Baumgartner, Hakimeh Ebrahimi-Nik, Arvin Iracheta‐Vellve et al. · Nature · 2023 · 174 citations · Full text

Life Sciences, Immunology, Pharmacology +17

PERCEPTION predicts patient response and resistance to treatment using single-cell transcriptomics of their tumors

Sanju Sinha, Rahulsimham Vegesna, Sumit Mukherjee et al. · Nature Cancer · 2024 · 98 citations

Life Sciences, Bioinformatics, Oncology +14

Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity

Meng‐Ju Wu, Hiroshi Kondo, Ashwin V. Kammula et al. · Science · 2024 · 89 citations · Full text

Medicine, Cancer Biology, Molecular Biology +12

Outcome differences by sex in oncology clinical trials

Ashwin V. Kammula, Alejandro A. Schäffer, Padma Sheila Rajagopal et al. · Nature Communications · 2024 · 56 citations · Full text

Medicine, Oncology, Cancer Drug Toxicity Management +11

DNAJB1-PRKACA Fusion Drives Fibrolamellar Liver Cancer through Impaired SIK Signaling and CRTC2/p300-Mediated Transcriptional Reprogramming

Ilaria Gritti, Jinkai Wan, Vajira Weeresekara et al. · Cancer Discovery · 2024 · 14 citations · Full text

Medicine, Cancer Biology, Oncology +17